Showing results (1-10 of 39) with videos related to
Sort By:
Pageof 4
Atherosclerosis|July 24, 2025
Effect of olezarsen on lipoprotein-associated ApoC-III levels in patients with familial chylomicronemia syndromeXiaohong Yang, Veronica J Alexander, Shuting Xia, et al.Journal of Clinical Lipidology|July 10, 2025
Effect of olezarsen on routinely measured lipase and amylase levels in familial chylomicronemia syndromeVeronica J Alexander, Thomas A Prohaska, Ewa Karwatowska-Prokopczuk, et al.Journal of Clinical Lipidology|May 10, 2023
APOC3 inhibition with volanesorsen reduces hepatic steatosis in patients with severe hypertriglyceridemiaThomas A Prohaska, Veronica J Alexander, Ewa Karwatowska-Prokopczuk, et al.American Journal of Preventive Cardiology|December 11, 2025
Clinical considerations for the treatment of patients with familial chylomicronemia syndrome using a hepatic-targeted <i>APOC3</i> antisense oligonucleotideArchna Bajaj, Elif A Oral, Alan Brown, et al.Nucleic Acid Therapeutics|June 27, 2020
Treatment with Volanesorsen, a 2'-O-Methoxyethyl-Modified Antisense Oligonucleotide Targeting <i>APOC3</i> mRNA, Does Not Affect the QTc Interval in Healthy VolunteersLynnetta M Watts, Ewa Karwatowska-Prokopczuk, Eunju Hurh, et al.European Heart Journal|July 23, 2019
N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levelsVeronica J Alexander, Shuting Xia, Eunju Hurh, et al.Journal of Clinical Lipidology|January 23, 2025
Differential effects of volanesorsen on apoC-III, triglycerides and pancreatitis in familial chylomicronemia syndrome diagnosed by genetic or non-genetic criteriaSotirios Tsimikas, Henry N Ginsberg, Veronica J Alexander, et al.Journal of Clinical Lipidology|August 21, 2025
Brief communication: Strong concordance of the North American Familial Chylomicronemia Syndrome Score with a positive genetic diagnosis in patients from the Balance studyAlan S Brown, Philippe Moulin, Andrew Dibble, et al.Journal of Lipid Research|February 6, 2016
Reduction in lipoprotein-associated apoC-III levels following volanesorsen therapy: phase 2 randomized trial resultsXiaohong Yang, Sang-Rok Lee, Yun-Seok Choi, et al.European Journal of Preventive Cardiology|July 30, 2025
Plasma reduction of apolipoprotein C-III with olezarsen leads to significant reductions in postprandial triglyceride levels: Results from a randomized trialJordan M Kraaijenhof, Merel C Peletier, Nick S Nurmohamed, et al.Pageof 4